

Gastroenterology

Volume 168 / Issue 2

February 2025

www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER

Gastroenterology



Restoring Healthy Growth: CP101 for Prevention of Recurrent CDI. See article by Allegretti, et al, page 357 for additional information.

COMMENTARIES

195 Taming Lynch Syndrome: The Remarkable Power of Prevention for One Family

M. B. Yurgelun, J. Rhees, N. Papadopoulos, B. Vogelstein, and C. R. Boland

200 Challenging Conventional Care: Ethical Considerations of De-intensification of Therapy in IBD

J. St-Pierre and D. T. Rubin

DIVERSITY, EQUITY, AND INCLUSION IN GI

205 Continuing the Commitment to Diversity, Equity, and Inclusion Within AGA Journals

S. M. Quezada and F. P. May

MENTORING, EDUCATION, AND TRAINING CORNER

210 A "How-to" Guide for Establishing an Effective Trainee Mentorship Program

K. Lithgow, J. Iannuzzi, K. Hurd, and S. Li

EDITORIALS

215 Burn the Fat: Colon Cancer Tumors Are Skilled at Lipid Storage During Obesity

A. L. Theiss and C. S. Williams

See Ghimire J et al on page 286.

217 Surveillance for Hepatocellular Carcinoma in Cirrhosis: End of Monopoly for Serum Alpha Fetoprotein

L.-Y. Mak and M.-F. Yuen

See Marsh TL et al on page 316.



Video



Related article in CGH



Hot Papers From New Investigators



CME quiz



Editorial accompanies this article



Additional online content available



Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2025 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

219 The New Horizon of *Clostridioides difficile* Infection Treatment*E. J. Kuijper and K. W. Garey*

See Allegretti JR et al on page 357.

GASTRO CURBSIDE CONSULT**223 An Unusual Cause of Acute Liver Failure Diagnosed on Organ Explant in a Patient With Ulcerative Colitis***A. Pedicelli, R. P. Michel, and G. Sebastiani***227 The Mysterious Cause of Refractory Diarrhea and Weight Loss in a Young Woman***Z. Fan, Y. Shi, and J. Liang***ELECTRONIC GASTRO CURBSIDE CONSULT**For a full list, please see the table of contents online at www.gastrojournal.org.**GASTRO GRAND ROUNDS****231 Alcohol-Associated Liver Disease: Managing the Dual Pathology of Liver Disease and of Alcohol Use Disorder***J. P. Arab, A. Louvet, M. Thiele, G. S. Winder, R. J. Wong, and A. K. Singal***REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY****245 The Role of DNA Methylation in Gastrointestinal Disease: An Expanded Review of Malignant and Nonmalignant Gastrointestinal Diseases***A. Kalra and S. J. Meltzer***GUIDELINES****267 AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals***F. S. Ali, M. H. Nguyen, R. Hernaez, D. Q. Huang, J. Wilder, A. Piscocoy, T. G. Simon, and Y. Falck-Ytter***285 Spotlight: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals***F. S. Ali, M. H. Nguyen, R. Hernaez, D. Q. Huang, J. Wilder, A. Piscocoy, T. G. Simon, and Y. Falck-Ytter***ORIGINAL RESEARCH****Full Reports****GI Cancer****286 Obesity-Facilitated Colon Cancer Progression Is Mediated by Increased Diacylglycerol O-Acyltransferases 1 and 2 Levels***J. Ghimire, M. E. Collins, P. Snarski, A. N. King, E. Ruiz, R. Iftikhar, H. M. Penrose, K. Moroz, T. Rorison, M. Baddoo, M. A. Naeem, A. H. Zea, S. T. Magness, E. F. Flemington, S. E. Crawford, and S. D. Savkovic*

See editorial on page 215.

Increased levels of diacylglycerol o-acyltransferases 1 and 2, which drive lipid droplet accumulation in human colon cancer, via a novel mechanism, may offer new therapeutic targets for treating colon cancer in obese patients.

300 Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling*M. Rathore, K. Curry, W. Huang, M. Wright, D. Martin, J. Baek, D. Taylor, M. Miyagi, W. Tang, H. Feng, Y. Li, Z. Wang, H. Graor, J. Willis, E. Bryson, C. S. Boutros, O. Desai, B. N. Islam, L. M. Ellis, S. E. Moss, J. M. Winter, J. Greenwood, and R. Wang*

Surrounding liver endothelium enhances growth of colorectal cancer liver metastases by secreting leucine-rich alpha-2-glycoprotein 1 for activating a cell surface protein human epidermal growth factor receptor 3 in cancer cells.

316 **A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis**

T. L. Marsh, N. D. Parikh, L. R. Roberts, M. E. Schwartz, M. H. Nguyen, A. Befeler, S. Page-Lester, N. Tayob, S. Srivastava, J. A. Rinaudo, A. G. Singal, K. R. Reddy, and J. A. Marrero

See editorial on page 217.

Better surveillance tests for hepatocellular carcinoma are needed. The authors performed a large prospective study to compare α -fetoprotein to GALAD for the detection of liver cancer. The authors showed that GALAD was more sensitive and specific for the diagnosis of liver cancer in patients with liver cirrhosis.

Inflammatory Bowel Disease

327 **Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4⁺ T Cells as Predictors for Response to Integrin $\alpha 4\beta 7$ -Blocking Therapy in Inflammatory Bowel Disease**

V. Horn, C. A. Cancino, L. M. Steinheuer, B. Obermayer, K. Fritz, A. L. Nguyen, K. S. Juhra, C. Plattner, D. Bösel, L. Oldenburg, M. Burns, A. R. Schulz, M. Saliutina, E. Mantzivi, D. Lissner, T. Conrad, M.-F. Mashregi, S. Zundler, E. Sonnenberg, M. Schumann, L.-M. Haag, D. Beule, L. Flatz, TRR241 IBDome Consortium, Z. Trajanoski, G. D'Haens, C. Weidinger, H. E. Mei, B. Siegmund, K. Thurley, and A. N. Hegazy

Despite the success of the anti-integrin antibody vedolizumab, few patients experience a sustained response. A comprehensive framework of nonresponse features is provided by harnessing multi-omics technologies and machine learning.

344 **Placebo Rates in Crohn's Disease Randomized Clinical Trials: An Individual Patient Data Meta-Analysis**

V. Solitano, M. Hogan, S. Singh, S. Danese, L. Peyrin-Biroulet, G. Zou, Y. Yuan, B. E. Sands, B. G. Feagan, P. S. Dulai, N. Narula, C. Ma, and V. Jairath

Results from individual patients with Crohn's disease were analyzed to better understand how patients who do not receive treatment in a clinical trial (the control group) will respond.

Gut Microbiota

357 **Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent *Clostridioides difficile* Infection: A Phase 2 Randomized Controlled Trial**

J. R. Allegretti, C. R. Kelly, T. Louie, M. Fischer, S. Hota, B. Misra, N. W. Van Hise, E. Yen, J. S. Bullock, M. Silverman, I. Davis, S. K. McGill, D. S. Pardi, R. Orenstein, A. Grinspan, N. El-Nachef, P. Feuerstadt, T. J. Borody, S. Khanna, S. Budree, and Z. Kassam

See editorial on page 219.

In patients with recurrent *Clostridioides difficile* infection due to a disruption in their gut bacteria after antibiotic use, CP101, an oral microbiome therapeutic, was better than placebo at preventing recurrent infection.

Hepatobiliary

367 **Longitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi*ZZ Genotype)**

M. Fromme, A. Payancé, M. Mandorfer, K. H. Thorhauge, M. Pons, M. Miravittles, J. Stolk, B. van Hoek, G. Stirnimann, S. Frankova, J. Sperl, A. E. Kremer, B. Burbaum, C. Schrader, A. Kadioglu, M. Walkenhaus, C. V. Schneider, F. Klebingat, L. Balcar, N. N. Kappe, B. Schaefer, J. Chorostowska-Wynimko, E. Aigner, S. Genslueckner, P. Striedl, P. Roger, J. Ryan, S. Roche, M. Vögelin, A. Ala, H. Bantel, J. Verbeek, Z. Mariño, M. Praktiknjo, T. J. G. Gevers, P. A. Reuken, T. Berg, J. George, M. Demir, T. Bruns, C. Trautwein, H. Zoller, M. Trauner, J. Genesca, W. J. Griffiths, V. Clark, A. Krag, A. M. Turner, N. G. McElvaney, and P. Strnad

Noninvasive liver fibrosis surrogates are superior to lung parameters for prediction of organ-related outcomes. Liver disease progresses primarily in those with risk factors/signs of liver injury.

RESEARCH LETTERS

- 382** **Use of Large Language Models to Identify Surveillance Colonoscopy Intervals—A Feasibility Study**
V. Acharya, V. Kumaresan, J. England, S. Mehta, D. Sussman, and A. Deshpande
- 385** **Early Life Exposure to Parental Crohn's Disease Is Associated With Offspring's Gut Microbiome, Gut Permeability, and Increased Risk of Future Crohn's Disease**
S.-H. Lee, M. Bushra, L. Qiu, A. M. Griffiths, W. Turpin, K. Croitoru, Crohn's and Colitis Canada-Genetic, Environmental, Microbial (CCC-GEM) Project Research Consortium
- 389** **Engineering Therapeutic Regulatory T Cells to Overexpress G Protein-Coupled Receptor 15 Improves Functional Fitness for In Vivo Gut Homing**
T. M. Müller, L.-J. Liu, M. Wiesinger, TRR241 IBDome Consortium, M. F. Neurath, C. J. Voskens, and S. Zundler
- 393** **Prospective Analysis of Liver Stiffness Measurement by Vibration Controlled Transient Elastography as a Predictor of Outcomes in Biliary Atresia**
J. P. Molleston, N. P. Goodrich, W. Ye, D. H. Leung, R. J. Sokol, B. L. Shneider, and ChILDRen FORCE Outcomes Working Group

CLINICAL PRACTICE UPDATES

- 396** **AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review**
J. P. E. Davis, J. K. Lim, F. F. Francis, and J. Ahn
- 405** **AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review**
S. C. Shah, A. Y. Wang, M. B. Wallace, and J. H. Hwang

GASTRO DIGEST

- 417** **Reevaluating Stemness in the Intestinal Crypt**
S. Asfaha and N. L. Jones
- 418** **A Brain-Gut Pathway for Stress-Induced Microbiome Changes**
S. A. Najjar and K. G. Margolis
- 418** **Minimal Incremental Benefits of Computer-Aided Optical Diagnosis of Colorectal Polyp Histology in a Large Prospective Cohort**
N. Forbes
- 419** **High Pathological Response Rate After Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer (NICHE-2 Study)**
V. Sallinen

CORRESPONDENCE

- 421** **Insights Into the Protective Role of GLP-1RAs in the Treatment of Type 2 Diabetes Mellitus: Implications for Hepatocellular Carcinoma and Hepatic Dysfunction**
Z. Wang, J. Li, and Y. Li
- 422** **Methodology of Study on GLP-1 Receptor Agonists and Hepatocellular Carcinoma Risk**
J. C.-C. Wei, P. Kuo, and Q. Mei

- 422 GLP-1 Receptor Agonists' Role in Reducing Hepatocellular Carcinoma Risk**
Z. Liu, D. Shan, and X. Han
- 424 Comments on "Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes"**
J. C.-C. Wei, C.-N. Wu, and W.-C. Cheng
- 425 Reply**
R. Xu
- 425 CHRONICLE Trial: How Cool Is Cold Snaring for Endoscopic Mucosal Resection?**
A. Tiwari
- 426 Detailed Information on Cold Snare Resection in Large Colorectal Polyps**
K. Nakajima, H. Saito, and Y. Nishikawa
- 427 Enhancing Cold Snare Endoscopic Mucosal Resection: Addressing Efficacy Concerns and Margin Management**
J. Xu and X. Tang
- 428 Evaluation of the Cold vs Hot Snare Endoscopic Resection of Large Nonpedunculated Colorectal Polyps in the German CHRONICLE Trial**
Y. Yang, Y. Li, C. Huang, T. Yu, and J. Li
- 429 Reply**
I. Steinbrück
- 430 Assessing the Preventative Effects of Vonoprazan Relative to Intravenous Proton Pump Inhibitors Following Endoscopic Intervention in Peptic Ulcers**
W.-Z. Tang, T.-H. Liu, and Y.-B. Li
- 431 Reply**
T. Geeratragoon and U. Kaosombattwattana
- 432 FIT-Positive Individuals: Is Timely Upper GI Endoscopy Necessary?**
Y. Nie, J. Lv, and J. Yan
- 433 Comments on "Risk of Cancers Proximal to the Colon in Fecal Immunochemical Test Positive Screeners in a Colorectal Cancer Screening Program"**
X.-H. Zhang, Y. Liu, Y.-X. Gao, J. C.-C. Wei, and L.-Y. Zhang
- 435 Esophagogastroduodenoscopy for Positive Fecal Immunochemical Test Screeners? Much Done, More to Be Considered**
L. Yi, X. Ren, and Z. Cheng
- 436 Regarding "Risk of Cancers Proximal to the Colon in Fecal Immunochemical Test Positive Screeners in a Colorectal Cancer Screening Program"**
J. Wu, Z. Zhang, and L. Zhang

100-10001-001
CENTER CITY, NY 10001-001
831 MAIN ST
JANE DOE
100-10001-001

100-10001-001
CENTER CITY, NY 10001-001
831 MAIN ST
JANE DOE
100-10001-001

[illegible]

Access to the full content of Gastroenterology Online is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

Your Account Number

**Sample
mailing
label**

GAST0000101864

JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

1GAST V91-4 1234567-8

1GASTV91-4 1284387-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001